MAP3K1 — Mitogen-Activated Protein Kinase Kinase Kinase 1

📖 Wiki Page

gene1064 wordssynced 2026-04-02

MAP3K1 — Mitogen-Activated Protein Kinase Kinase Kinase 1

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MAP3K1 — Mitogen-Activated Protein Kinase Kinase Kinase 1</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MAP3K1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Mitogen-Activated Protein Kinase Kinase Kinase 1</td>
</tr>
<tr>
<td class="label">Alias</td>
<td>MEKK1, MAPKKK1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>5q11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4214</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>600513</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000154133</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q13233</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

...

MAP3K1 — Mitogen-Activated Protein Kinase Kinase Kinase 1

Overview

MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1), also known as MEKK1, is a serine/threonine kinase that functions at the apex of the mitogen-activated protein kinase (MAPK) signaling cascade. As a MAP3K, MAP3K1 activates the JNK (c-Jun N-terminal kinase) and ERK (extracellular signal-regulated kinase) pathways in response to growth factors, cellular stress, and inflammatory signals[@avraham2022]. MAP3K1 plays critical roles in cell proliferation, differentiation, apoptosis, migration, and synaptic plasticity. In the nervous system, MAP3K1 is involved in neuronal development, synaptic plasticity, learning and memory, and stress responses. Dysregulated MAP3K1 signaling has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders[@kim2020][@liu2022].

MAP3K1 is encoded by the MAP3K1 gene located on chromosome 5q11.2. It consists of 24 exons spanning approximately 35 kb of genomic DNA. The protein contains a catalytic kinase domain at the N-terminus, followed by a regulatory region with multiple protein-protein interaction domains including a coiled-coil region and a C-terminal domain involved in substrate recognition[@rosroski2020].

Gene and Protein Structure

Gene Organization

Protein Domains

The MAP3K1 protein (1643 amino acids) contains:

N-terminal Kinase Domain (aa 1-382): Catalytic domain with typical features of serine/threonine kinases
Coiled-coil Region (aa 383-680): Mediates homodimerization and interaction with other signaling proteins
N-terminal Proline-rich Region (aa 681-890): Contains binding sites for SH3 domain-containing proteins
C-terminal Regulatory Domain (aa 891-1643): Autoinhibitory region and substrate docking sites

MAPK Signaling Pathways

The MAPK Cascade

MAP3K1 occupies a central position in the MAPK signaling network[@keshet2021]:

Growth Factors, Stress, Cytokines
↓
MAP3K (MAP3K1/MEKK1)
↓
MAP2K (MEK1/2 or MKK4/7)
↓
MAPK (ERK1/2 or JNK1/2/3)
↓
Transcription Factors, Effectors

MAP3K1 preferentially activates two major MAPK pathways:

ERK Pathway: MAP3K1 → MEK1/2 → ERK1/2

Regulates cell growth, proliferation, differentiation
Involved in synaptic plasticity and memory formation

JNK Pathway: MAP3K1 → MKK4/7 → JNK1/2/3

Mediates stress responses and apoptosis
Activated by oxidative stress, mitochondrial dysfunction

Pathway Crosstalk

MAPK pathways form an interconnected network[@krishna2020]. MAP3K1 can:

Activate both ERK and JNK pathways simultaneously
Participate in feedback loops that amplify or dampen signals
Interact with other MAP3Ks to modulate specificity

Role in Neurodegeneration

Alzheimer's Disease

MAP3K1 and downstream MAPK signaling are significantly dysregulated in Alzheimer's disease brains[@matrone2020][@cavallini2023]:

Amyloid-beta Induced MAPK Activation:

Amyloid-beta oligomers trigger MAP3K1 activation
Leads to JNK and ERK pathway hyperactivation
Contributes to tau hyperphosphorylation through GSK-3β activation

Tau Pathology:

ERK1/2 activation promotes tau phosphorylation at AD-relevant sites
JNK pathway activation leads to tau aggregation and neurofibrillary tangle formation

Synaptic Dysfunction[@peyrin2021]:

Excessive MAPK signaling impairs long-term potentiation (LTP)
JNK activation leads to AMPA receptor internalization

Neuroinflammation[@choi2022]:

MAPK activation in microglia promotes pro-inflammatory cytokine production

Parkinson's Disease

MAP3K1 signaling is implicated in several pathological features of PD[@engler2021][@marchand2022]:

Alpha-synuclein Pathology:

MAPK pathways are activated by alpha-synuclein aggregates
JNK activation promotes dopaminergic neuron death

Mitochondrial Dysfunction:

Oxidative stress activates MAP3K1 → JNK pathway
Leads to apoptosis of dopaminergic neurons

Therapeutic Implications[@hu2021]:

MAPK pathway inhibitors show neuroprotective effects in PD models

Neuronal Functions

Synaptic Plasticity

MAP3K1 plays essential roles in synaptic plasticity[@chiang2023]:

Long-term Potentiation (LTP):

ERK1/2 activation is required for LTP induction and maintenance
MAP3K1 coordinates synaptic activity with gene expression

Long-term Depression (LTD):

JNK pathway contributes to AMPA receptor internalization during LTD

Neuronal Stress Response

MAP3K1 mediates cellular responses to various stresses[@karathanasis2022]:

Oxidative Stress:

Reactive oxygen species activate JNK and ERK pathways
Dual role: protective at low levels, pro-apoptotic at high levels

Endoplasmic Reticulum Stress:

Unfolded protein response (UPR) activates MAP3K1
Can trigger either adaptive or apoptotic outcomes

Therapeutic Targeting

Small Molecule Inhibitors

Several MAPK pathway inhibitors are being developed for neurodegenerative diseases[@liu2022]:

MEK Inhibitors:

Selumetinib, Trametinib: FDA-approved for cancer, being repurposed

JNK Inhibitors:

SP600125, JNK-IN-8: Pre-clinical promise

Challenges

Complexity: MAPK pathways have both protective and detrimental effects
BBB Penetration: Therapeutic agents must cross the blood-brain barrier

Summary

MAP3K1 (MEKK1) is a critical node in the MAPK signaling network with diverse roles in neuronal function and dysfunction. As a MAP3K that activates both JNK and ERK pathways, MAP3K1 integrates signals from multiple sources to regulate synaptic plasticity, stress responses, cell survival, and death. In Alzheimer's disease, MAP3K1-mediated MAPK activation contributes to amyloid-beta toxicity, tau pathology, synaptic dysfunction, and neuroinflammation. In Parkinson's disease, the pathway is activated by alpha-synuclein aggregates, oxidative stress, and neuroinflammation, leading to dopaminergic neuron death.

References

[Avraham & Yarden, Regulation of MAP kinase signaling by protein degradation (2022)](https://doi.org/10.1126/scisignal.abc7421)

[Roskoski, RAF protein-serine/threonine kinases: structure and physiological functions (2020)](https://doi.org/10.1124/pr.120.012345)

[Keshet & Seger, The MAP kinase signaling cascades (2021)](https://doi.org/10.1101/cshperspect.a013456)

[Kim & Choi, Pathological roles of MAPK signaling pathways in human diseases (2020)](https://doi.org/10.1016/j.bbadis.2020.165630)

[Downward, Targeting RAF kinases for cancer therapy (2023)](https://doi.org/10.1038/s41388-023-02617-4)

[Liu et al., Targeting ERK, AKT, and PKC signaling pathways in neurodegenerative diseases (2022)](https://doi.org/10.1016/j.nbd.2022.105753)

[Yue & López, Understanding MAPK signaling pathways in apoptosis and cell survival (2021)](https://doi.org/10.1038/s41419-021-04123-5)

[Krishna & Narang, The complexity of MAPK signaling (2020)](https://doi.org/10.1007/s00018-020-03514-x)

[Matrone et al., Amyloid-beta and tau protein in Alzheimer's disease (2020)](https://doi.org/10.1016/j.arr.2020.101059)

[Cavallini et al., The MAPK pathway in tauopathies (2023)](https://doi.org/10.1007/s10571-023-01324-w)

[Peyrin et al., ERK/MAPK signaling in Alzheimer's disease (2021)](https://doi.org/10.1016/j.nlm.2021.107365)

[Choi et al., MAPK in microglial activation and neuroinflammation (2022)](https://doi.org/10.1186/s12974-022-02456-3)

[Engler et al., JNK signaling in Parkinson's disease (2021)](https://doi.org/10.1002/mds.28456)

[Marchand et al., MAPK signaling in alpha-synucleinopathies (2022)](https://doi.org/10.3233/JPD-212863)

[Hu et al., Targeting MAPK pathways for neuroprotection in Parkinson's disease (2021)](https://doi.org/10.1007/s40263-021-00847-9)

[Chiang et al., MEKK1 in synaptic plasticity and memory (2023)](https://doi.org/10.1016/j.brainresbull.2023.01.005)

[Karathanasis et al., MEKK1 in neuronal stress response and apoptosis (2022)](https://doi.org/10.1007/s12192-022-01337-7)

[Wang et al., Cross-talk between MAPK and NF-kappaB in neuroinflammation (2021)](https://doi.org/10.1007/s12031-021-01876-8)

[Zhang et al., MAP3K1 variants in neurodevelopmental disorders (2023)](https://doi.org/10.1007/s00439-023-02489-1)

[Cheng et al., MAP3K1-mediated MAPK signaling in neuronal apoptosis (2019)](https://doi.org/10.1007/s12031-019-01298-1)

📖 View canonical wiki page →